{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T17:47:54Z","timestamp":1777657674341,"version":"3.51.4"},"reference-count":42,"publisher":"MDPI AG","issue":"9","license":[{"start":{"date-parts":[[2023,8,23]],"date-time":"2023-08-23T00:00:00Z","timestamp":1692748800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Medicina"],"abstract":"<jats:p>Background: Rheumatoid arthritis (RA) is a chronic systemic autoimmune and inflammatory disease. Conventional synthetic and biologic disease-modifying antirheumatic drugs (DMARDs), Janus kinase inhibitors, and rituximab are used to treat the disease. There are no recommendations or guidelines for the treatment of patients with both inflammatory arthritis and end-stage renal disease (ESRD), despite the safety and efficacy of the mentioned drugs. The anti-interleukin-6 receptor antibody tocilizumab (TCZ) has not been used as a long-term therapy for hemodialysis (HD) patients with RA, except in a few case reports. Case Description: We present the case of a 41-year-old patient with RA and ESRD on maintenance HD due to type 1 diabetes-related complications. Due to high RA disease activity, the patient was not a suitable candidate for a kidney transplant. Because TCZ is used to treat both RA and kidney transplant rejection, therapy with a full dose of TCZ was administered. The patient has achieved sustained clinical remission (for the past four years) with no adverse events reported. Conclusions: Herein, we present the safe and effective use of TCZ in an RA patient on HD who is also a candidate for kidney transplant. Consequently, TCZ could be the treatment of choice for RA patients with ESRD who have not achieved disease control (low activity or remission) with conventional synthetic DMARDs. Clinical studies are required to evaluate the efficacy and safety of biologic DMARDs and Janus kinase inhibitors in patients with both inflammatory arthritis and ESRD.<\/jats:p>","DOI":"10.3390\/medicina59091517","type":"journal-article","created":{"date-parts":[[2023,8,23]],"date-time":"2023-08-23T10:28:05Z","timestamp":1692786485000},"page":"1517","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Safe and Efficient Use of Tocilizumab in Rheumatoid Arthritis Patient on Maintenance Hemodialysis: A Case Report"],"prefix":"10.3390","volume":"59","author":[{"given":"Paula","family":"Kili\u0107","sequence":"first","affiliation":[{"name":"Department of Clinical Immunology, Rheumatology, and Pulmonology, University Hospital Sveti Duh, 10000 Zagreb, Croatia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lucija","family":"Iki\u0107","sequence":"additional","affiliation":[{"name":"Department of Anatomy and Physiology, University of Applied Health Sciences, 10000 Zagreb, Croatia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miroslav","family":"Mayer","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, School of Medicine, University of Zagreb, 10000 Zagreb, Croatia"},{"name":"Division of Clinical Immunology and Rheumatology, University Hospital Centre Zagreb, 10000 Zagreb, Croatia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marinko","family":"Artukovi\u0107","sequence":"additional","affiliation":[{"name":"Department of Clinical Immunology, Rheumatology, and Pulmonology, University Hospital Sveti Duh, 10000 Zagreb, Croatia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ksenija","family":"Ma\u0161trovi\u0107 Radon\u010di\u0107","sequence":"additional","affiliation":[{"name":"Department of Physical Medicine and Rehabilitation, University Hospital Sveti Duh, 10000 Zagreb, Croatia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marina","family":"Iki\u0107 Matija\u0161evi\u0107","sequence":"additional","affiliation":[{"name":"Department of Clinical Immunology, Rheumatology, and Pulmonology, University Hospital Sveti Duh, 10000 Zagreb, Croatia"},{"name":"Department of Internal Medicine, School of Medicine, University of Zagreb, 10000 Zagreb, Croatia"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2023,8,23]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1007\/s10787-018-0458-0","article-title":"IL-6 signalling pathways and the development of type 2 diabetes","volume":"26","author":"Akbari","year":"2018","journal-title":"Inflammopharmacology"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.cyto.2017.01.002","article-title":"Correlation between serum interleukin-6 level and type 1 diabetes mellitus: A systematic review and meta-analysis","volume":"94","author":"Chen","year":"2017","journal-title":"Cytokine"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1093\/ndt\/gfu233","article-title":"Interleukin-6 in renal disease and therapy","volume":"30","author":"Jones","year":"2015","journal-title":"Nephrol. Dial. Transpl."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"2673","DOI":"10.1007\/s10067-017-3804-5","article-title":"Prevalence of and factors associated with renal dysfunction in rheumatoid arthritis patients: A cross-sectional study in community hospitals","volume":"36","author":"Mori","year":"2017","journal-title":"Clin. Rheumatol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1016\/j.semarthrit.2016.07.016","article-title":"End-stage renal disease in patients with rheumatoid arthritis","volume":"46","author":"Paudyal","year":"2017","journal-title":"Semin. Arthritis Rheum."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1865","DOI":"10.1007\/s40265-017-0829-7","article-title":"Tocilizumab: A Review in Rheumatoid Arthritis","volume":"77","author":"Scott","year":"2017","journal-title":"Drugs"},{"key":"ref_7","unstructured":"(2023, July 20). Tocilizumab: Drug Information. Available online: https:\/\/www.uptodate.com\/contents\/tocilizumab-drug-information?sectionName=Kidney%20Impairment%20(Adult)&topicId=10208&search=tocilizumab&usage_type=panel&anchor=F50991682&source=panel_search_result&selectedTitle=1~148&showDrugLabel=true&kp_tab=drug_general&display_rank=1#F50991682."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1002\/psp4.12224","article-title":"Pharmacokinetics of Monoclonal Antibodies","volume":"6","author":"Ryman","year":"2017","journal-title":"CPT Pharmacomet. Syst. Pharmacol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1016\/S0140-6736(08)60453-5","article-title":"Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): A double-blind, placebo-controlled, randomised trial","volume":"371","author":"Smolen","year":"2008","journal-title":"Lancet"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"2817","DOI":"10.1002\/art.22033","article-title":"Double-blind randomized controlled clinical trial of the interleukin-6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate","volume":"54","author":"Maini","year":"2006","journal-title":"Arthritis Rheum."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"2968","DOI":"10.1002\/art.23940","article-title":"Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: The tocilizumab in combination with traditional disease-modifying antirheumatic drug therapy study","volume":"58","author":"Genovese","year":"2008","journal-title":"Arthritis Rheum."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.pulmoe.2020.07.003","article-title":"Rationale and evidence on the use of tocilizumab in COVID-19: A systematic review","volume":"27","author":"Cortegiani","year":"2021","journal-title":"Pulmonology"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1007\/s10753-013-9598-y","article-title":"Association between IL-6 concentration and diabetes-related variables in DM1 patients with and without microvascular complications","volume":"36","author":"Wegner","year":"2013","journal-title":"Inflammation"},{"key":"ref_14","first-page":"169","article-title":"Importance of inflammatory markers and IL-6 for diagnosis and follow up of patients with type 2 diabetes mellitus","volume":"14","author":"Malenica","year":"2017","journal-title":"Med. Glas."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1681\/ASN.2007091048","article-title":"The role of inflammatory cytokines in diabetic nephropathy","volume":"19","year":"2008","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"405","DOI":"10.3389\/fimmu.2017.00405","article-title":"Interleukin-6 Signaling Pathway and Its Role in Kidney Disease: An Update","volume":"21","author":"Su","year":"2017","journal-title":"Front. Immunol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"2381","DOI":"10.1111\/ajt.14228","article-title":"Assessment of Tocilizumab (Anti-Interleukin-6 Receptor Monoclonal) as a Potential Treatment for Chronic Antibody-Mediated Rejection and Transplant Glomerulopathy in HLA-Sensitized Renal Allograft Recipients","volume":"17","author":"Choi","year":"2017","journal-title":"Am. J. Transpl."},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Weinhard, J., Noble, J., Jouve, T., Malvezzi, P., and Rostaing, L. (2021). Tocilizumab and Desensitization in Kidney Transplant Candidates: Personal Experience and Literature Review. J. Clin. Med., 10.","DOI":"10.3390\/jcm10194359"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1007\/s00296-010-1430-5","article-title":"Effective and safe administration of tocilizumab to a patient with rheumatoid arthritis on haemodialysis","volume":"31","author":"Iwamoto","year":"2011","journal-title":"Rheumatol. Int."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"37","DOI":"10.3109\/13506129.2011.636460","article-title":"Tocilizumab improves cardiac disease in a hemodialysis patient with AA amyloidosis secondary to rheumatoid arthritis","volume":"19","author":"Hattori","year":"2012","journal-title":"Amyloid"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1136\/annrheumdis-2014-206695","article-title":"Effectiveness and safety of tocilizumab therapy for patients with rheumatoid arthritis and renal insufficiency: A real-life registry study in Japan (the ACTRA-RI study)","volume":"74","author":"Mori","year":"2015","journal-title":"Ann. Rheum. Dis."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1007\/s10157-021-02126-4","article-title":"Clinical efficacy and safety of combination therapy of tocilizumab and steroid pulse therapy for critical COVID-19 in HD patients","volume":"26","author":"Toda","year":"2022","journal-title":"Clin. Exp. Nephrol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"2050313X211069023","DOI":"10.1177\/2050313X211069023","article-title":"Use of tocilizumab, remdesivir, and high-dose methylprednisolone prevents intubation in an ESRD patient with COVID-19 pneumonia","volume":"10","author":"Judge","year":"2022","journal-title":"SAGE Open Med. Case Rep."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1007\/s13730-020-00512-7","article-title":"Successful treatment of two Japanese ESRD cases with severe COVID-19 pneumonia","volume":"10","author":"Abe","year":"2021","journal-title":"CEN Case Rep."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1007\/s13730-021-00577-y","article-title":"Effective treatment with Tocilizumab in a COVID-19 patient on maintenance hemodialysis: A case report","volume":"10","author":"Chamaa","year":"2021","journal-title":"CEN Case Rep."},{"key":"ref_26","first-page":"8829309","article-title":"Tocilizumab Use in a Chronic Hemodialysis Patient for the Management of COVID-19-Associated Pneumonia and Acute Respiratory Distress Syndrome","volume":"2020","author":"Gupta","year":"2020","journal-title":"Case Rep. Nephrol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1111\/nep.13767","article-title":"Clinical benefits of Tocilizumab in COVID-19-related cytokine release syndrome in a patient with end-stage kidney disease on haemodialysis in Australia","volume":"25","author":"Stephen","year":"2020","journal-title":"Nephrology"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1007\/s00296-010-1452-z","article-title":"Etanercept treatment in patients with rheumatoid arthritis on dialysis","volume":"30","author":"Nakamura","year":"2010","journal-title":"Rheumatol. Int."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"68","DOI":"10.5152\/eurjrheum.2022.21099","article-title":"Anti-TNF treatment in ankylosing spondylitis patients with chronic kidney disease: Is it effective and safe?","volume":"9","author":"Pehlivan","year":"2022","journal-title":"Eur. J. Rheumatol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"2342","DOI":"10.1111\/ajt.15319","article-title":"Abatacept as rescue immunosuppression after calcineurin inhibitor treatment failure in renal transplantation","volume":"19","author":"Badell","year":"2019","journal-title":"Am. J. Transpl."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"10681","DOI":"10.3389\/ti.2022.10681","article-title":"Abatacept Rescue Therapy in Kidney Transplant Recipients: A Case Series of Five Patients","volume":"35","author":"Atenza","year":"2022","journal-title":"Transpl. Int."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1056\/NEJMoa2109927","article-title":"Cardiovascular and Cancer Risk with Tofacitinib in Rheumatoid Arthritis","volume":"386","author":"Ytterberg","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_33","first-page":"201","article-title":"Evaluation of VTE, MACE, and Serious Infections among Patients with RA Treated with Baricitinib Compared to TNFi: A Multi-Database Study of Patients in Routine Care Using Disease Registries and Claims Databases","volume":"10","author":"Salinas","year":"2023","journal-title":"Rheumatol. Ther."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1002\/jcph.178","article-title":"Pharmacokinetics of tofacitinib, a janus kinase inhibitor, in patients with impaired renal function and end-stage renal disease","volume":"54","author":"Krishnaswami","year":"2014","journal-title":"J. Clin. Pharmacol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1002\/jcph.1375","article-title":"Characterization of the Effect of Renal Impairment on Upadacitinib Pharmacokinetics","volume":"59","author":"Mohamed","year":"2019","journal-title":"J. Clin. Pharmacol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.2215\/CJN.10441015","article-title":"Biomarkers of Cardiovascular Disease and Mortality Risk in Patients with Advanced CKD","volume":"11","author":"Sun","year":"2016","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1136\/annrheumdis-2018-214367","article-title":"Risk of serious infections in tocilizumab versus other biologic drugs in patients with rheumatoid arthritis: A multidatabase cohort study","volume":"78","author":"Pawar","year":"2019","journal-title":"Ann. Rheum. Dis."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"2223","DOI":"10.1093\/rheumatology\/keaa557","article-title":"Incidence, risk factors and validation of the RABBIT score for serious infections in a cohort of 1557 patients with rheumatoid arthritis","volume":"60","author":"Thomas","year":"2021","journal-title":"Rheumatology"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1080\/0886022X.2018.1487857","article-title":"Changes in the inflammatory and oxidative stress markers during a single hemodialysis session in patients with chronic kidney disease","volume":"40","author":"Suchitra","year":"2018","journal-title":"Ren. Fail."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"iii35","DOI":"10.1093\/ndt\/gfy175","article-title":"Chronic inflammation in end-stage renal disease and dialysis","volume":"33","author":"Cobo","year":"2018","journal-title":"Nephrol. Dial. Transpl."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"S274","DOI":"10.1681\/ASN.2006080926","article-title":"Inflammatory syndrome in patients on hemodialysis","volume":"17","year":"2006","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1081\/JDI-100100878","article-title":"Interleukin-6 gene expression in peripheral blood mononuclear cells from patients undergoing hemodialysis or continuous ambulatory peritoneal dialysis","volume":"22","author":"Takahashi","year":"2000","journal-title":"Ren. Fail."}],"container-title":["Medicina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1648-9144\/59\/9\/1517\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T20:40:45Z","timestamp":1760128845000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1648-9144\/59\/9\/1517"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,23]]},"references-count":42,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2023,9]]}},"alternative-id":["medicina59091517"],"URL":"https:\/\/doi.org\/10.3390\/medicina59091517","relation":{},"ISSN":["1648-9144"],"issn-type":[{"value":"1648-9144","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8,23]]}}}